ADMP:NSD-Adamis Pharmaceuticals Corporation (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 0.37

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

0.47M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-30 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

+0.19 (+1.28%)

USD7.68B 496.00 5.94
MNTA Momenta Pharmaceuticals, Inc

+2.05 (+7.68%)

USD3.13B N/A -8.63
CRON Cronos Group Inc

+0.05 (+0.79%)

USD2.14B 11.60 N/A
IRWD Ironwood Pharmaceuticals, Inc

+0.53 (+5.41%)

USD1.55B 71.01 14.33
PCRX Pacira BioSciences, Inc

+1.98 (+6.24%)

USD1.36B 961.92 26.99
TCDA Tricida, Inc

+0.14 (+0.60%)

USD1.20B N/A -5.02
SUPN Supernus Pharmaceuticals, Inc

+1.09 (+6.78%)

USD0.90B 8.17 5.64
TLRY Tilray, Inc

-2.49 (-27.36%)

USD0.82B N/A -4.50
PAHC Phibro Animal Health Corporati..

+2.38 (+11.75%)

USD0.82B 21.55 11.30
AMPH Amphastar Pharmaceuticals, Inc

+1.06 (+7.54%)

USD0.65B 14.35 37.49

ETFs Containing ADMP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -47.14% 27% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.14% 27% F 17% F
Trailing 12 Months  
Capital Gain -82.46% 13% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.46% 13% F 6% F
Trailing 5 Years  
Capital Gain -90.61% 22% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -90.61% 22% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain -18.03% 44% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.03% 44% F 15% F
Risk Return Profile  
Volatility (Standard Deviation) 50.49% 36% F 21% F
Risk Adjusted Return -35.71% 45% F 21% F
Market Capitalization 0.02B 24% F 19% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.56 93% A 83% B
Price / Cash Flow Ratio -0.69 37% F 64% D
EV/EBITDA -0.43 38% F 64% D
Management Effectiveness  
Return on Equity -74.26% 46% F 17% F
Return on Invested Capital -85.07% 17% F 11% F
Return on Assets -37.54% 19% F 11% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.89 55% F 37% F
Short Percent 6.24% 60% D- 39% F
Beta 1.49 44% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector